Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAF(V600E/K)- mutated melanoma

PURPOSE: Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated. EXPERIMENTAL DESIGN: We conducted a phase II trial in melanoma patients whose tumors harbored a BRAF mutation....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Catalanotti, Federica, Solit, David B., Pulitzer, Melissa P., Berger, Michael F., Scott, Sasinya N., Iyriboz, Tunc, Lacouture, Mario E., Panageas, Katherine S., Wolchok, Jedd D., Carvajal, Richard D., Schwartz, Gary K., Rosen, Neal, Chapman, Paul B.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3932005/
https://ncbi.nlm.nih.gov/pubmed/23444215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3476
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak